Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 388,152	$ 401,803
Prepaid expenses and other current assets	626,760	764,964
Short-term note receivable - Marizyme	1,298,082
Total current assets	2,312,994	1,166,767
Other assets		866,481
Total Assets	2,312,994	2,033,248
Current liabilities
Accounts payable	1,638,447	2,222,983
Accrued expenses and other current liabilities	570,148	560,006
Warrant liabilities	274,042	54,600
Total current liabilities	4,453,845	4,136,805
Commitments and Contingencies (Note 10)
Qualigen Therapeutics, Inc. stockholders’ equity (deficit):
Common stock, $0.001 par value; 225,000,000 shares authorized; 548,284 and 107,243 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively	65,314	43,262
Additional paid-in capital	119,999,588	114,655,565
Accumulated deficit	(122,205,753)	(116,802,384)
Total Stockholders’ Deficit	(2,140,851)	(2,103,557)
Total Liabilities & Stockholders’ Deficit	2,312,994	2,033,248
Nonrelated Party [Member]
Current liabilities
Convertible debt	1,090,002
Derivative liabilities	368,288
Related Party [Member]
Current liabilities
Convertible debt	344,229	1,299,216
Derivative liabilities	$ 168,689